BioAge Labs (NASDAQ:BIOA) Shares Gap Down – Time to Sell?

BioAge Labs, Inc. (NASDAQ:BIOA)’s share price gapped down prior to trading on Wednesday . The stock had previously closed at $21.32, but opened at $20.13. BioAge Labs shares last traded at $21.0340, with a volume of 218,161 shares trading hands.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on BIOA shares. Wall Street Zen upgraded BioAge Labs from a “sell” rating to a “hold” rating in a research report on Sunday, January 18th. Citigroup lifted their price target on shares of BioAge Labs from $10.00 to $15.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of BioAge Labs in a report on Thursday, October 30th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, BioAge Labs presently has a consensus rating of “Hold” and an average target price of $15.00.

BioAge Labs Trading Down 0.5%

The stock’s fifty day simple moving average is $13.43 and its 200 day simple moving average is $8.18. The company has a market cap of $674.34 million, a price-to-earnings ratio of -12.38 and a beta of 1.38.

BioAge Labs (NASDAQ:BIOA) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.11. The company had revenue of $2.05 million during the quarter.

Insider Activity

In other BioAge Labs news, insider Paul D. Rubin sold 68,897 shares of BioAge Labs stock in a transaction dated Thursday, December 4th. The shares were sold at an average price of $10.19, for a total transaction of $702,060.43. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Dov A. Md Goldstein sold 27,000 shares of the business’s stock in a transaction dated Tuesday, January 13th. The shares were sold at an average price of $19.70, for a total transaction of $531,900.00. Following the completion of the transaction, the chief financial officer owned 22,408 shares in the company, valued at $441,437.60. The trade was a 54.65% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 347,004 shares of company stock valued at $5,673,859. 20.82% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Nisa Investment Advisors LLC increased its stake in BioAge Labs by 4,219.4% during the fourth quarter. Nisa Investment Advisors LLC now owns 10,237 shares of the company’s stock worth $135,000 after acquiring an additional 10,000 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in shares of BioAge Labs by 228.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 36,848 shares of the company’s stock worth $217,000 after purchasing an additional 25,638 shares during the period. Millennium Management LLC increased its position in shares of BioAge Labs by 749.8% during the 3rd quarter. Millennium Management LLC now owns 306,552 shares of the company’s stock worth $1,803,000 after purchasing an additional 270,479 shares during the last quarter. Bank of America Corp DE raised its holdings in BioAge Labs by 46.3% in the 3rd quarter. Bank of America Corp DE now owns 11,119 shares of the company’s stock valued at $65,000 after buying an additional 3,517 shares during the period. Finally, Occudo Quantitative Strategies LP acquired a new position in BioAge Labs in the third quarter valued at about $113,000.

BioAge Labs Company Profile

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.